Nyra health Raises €20M to Expand AI Neurotherapy

Key Takeaways

1. Vienna-based nyra health closed a €20 million Series A led by Armira Growth, with renewed backing from Wellington Partners, Crane Venture Partners (managing MassMutual Ventures’ portfolio), and EVER Pharma.
2. The platform is already live in 100+ neurological clinics and is reimbursed by 28+ statutory and private health insurers, covering over 40 million insured individuals in Germany alone.
3. Funds will fuel U.S. market entry alongside an international pharmaceutical partner, expansion across the DACH region, and a €4.2 million AI research project with leading U.S. universities.
4. The broader neurorehabilitation market is projected to grow from $2.46 billion in 2025 to $6.96 billion by 2035 at a 10.95% CAGR, driven by rising neurological disease prevalence and growing digital therapeutics adoption.​

Quick Recap

nyra health, a Vienna-based digital health company specializing in AI-driven neurological rehabilitation, has officially announced the close of a €20 million Series A funding round. The round was led by European growth investor Armira Growth, with continued participation from existing backers Wellington Partners, Crane Venture Partners, and pharmaceutical company EVER Pharma. The announcement was first shared publicly via social media by The SaaS News and confirmed through the company’s official channels and CEO Moritz Schollauf’s LinkedIn post.

How nyra health Is Innovating Neurotherapy with AI?

nyra health develops an AI-powered platform that supports neurological rehabilitation across the full patient care chain, from inpatient hospital stays through outpatient follow-up and long-term home-based therapy. Its flagship product, myReha, is an MDR Class IIa-certified medical device that enables patients recovering from strokes, traumatic brain injuries, dementia, and other neurological conditions to train speech, cognition, fine motor skills, and daily functional abilities through adaptive digital therapy.

The platform’s multimodal AI models analyze performance data including speech patterns, reaction times, error profiles, and training dynamics. Based on these metrics, therapy programs automatically adjust to a patient’s progress and fatigue levels. Specialized speech models assess pronunciation, word retrieval, syntax, and semantic structure, enabling a level of therapy personalization that goes beyond traditional digital rehabilitation tools.

Alongside myReha, the company offers nyra insights, a clinical management system for therapists that provides real-time monitoring of patient progress, therapy intensity, and outcome trends. An AI-supported Content Studio dynamically generates personalized therapy exercises, currently offering access to over 65,000 tasks across speech-language therapy, neuropsychology, and occupational therapy.

The clinical evidence is notable. The platform has been shown to improve health outcomes by an average of 26.2% across therapeutic domains upon completion of digital rehabilitation aftercare. Patient therapy adherence averaged over 4 hours per week, and 98% of patients rated the aftercare program as successful.​

The company was founded in Vienna by Moritz Schollauf (CEO, legal background), Dr. Philipp Schollauf (neurology), and Mario Zusag (ex-Google AI and IBM Research ML researcher), combining deep clinical, regulatory, and technical expertise. nyra health previously raised €4.5 million in an oversubscribed seed round in 2023, co-led by MassMutual Ventures and Wellington Partners.

Growing €65B Care Gap

The timing of this raise is significant. Neurological conditions such as stroke and dementia generate an estimated €65 billion in annual costs in Germany alone, largely driven by inadequate post-discharge care and insufficient long-term therapy intensity. Traditional rehabilitation pathways often decline sharply in frequency after hospital discharge, leaving patients without structured follow-up during the most critical recovery window.

Digital neurorehabilitation is increasingly recognized as the solution to this structural problem. The global neurorehabilitation market is projected to grow from $2.46 billion in 2025 to $6.96 billion by 2035 at a CAGR of 10.95%. Meanwhile, the digital neurotherapeutics segment specifically was valued at $362.63 million in 2025 and is expanding at a 19.5% CAGR.

nyra health is particularly well-positioned because its platform is already embedded in the German standard of care. myReha is recognized as a digital application within the standard care model of the German Pension Insurance (DRV), described as Europe’s largest rehabilitation provider. With automatic reimbursement from 28+ insurers covering 40 million+ insured individuals, the company has achieved a level of healthcare system integration that most digital therapeutics startups are still working toward.

The planned U.S. market entry adds a major growth dimension. The U.S. neurorehabilitation market alone is projected to grow from $0.94 billion in 2025 to $2.66 billion by 2035 at a CAGR of 10.98%. nyra health is preparing this launch in collaboration with an international pharmaceutical partner and is advancing its AI models through a €4.2 million research project with leading U.S. research universities.

Competitive Landscape

nyra health operates in the digital neurorehabilitation space, where its most relevant competitors at a comparable growth stage are Neurofenix (London, UK) and Constant Therapy Health (Boston, US). MindMaze, while a major player, operates at a vastly different scale with $340 million+ in total funding and a $1.5 billion valuation.

nyra health leads in regulatory standing and healthcare system integration, with its MDR Class IIa certification and automatic reimbursement across 28+ insurers giving it a structural advantage in the European market. Constant Therapy Health has the broadest consumer user base with 700,000+ individual users and strong brand recognition in the U.S. speech therapy space, making it a formidable presence in the direct-to-patient segment. Neurofenix differentiates through its hardware-software combination with the NeuroBall sensor device for upper limb rehabilitation, achieving 20x more movement repetitions at home versus other methods in clinical trials.

Bayelsa Watch’s Takeaway

I think this is a significant deal for the European digital health ecosystem, and here is why. In my experience covering healthtech funding, the real differentiator is never the AI itself; it is how deeply a company has embedded its product into existing healthcare reimbursement and clinical workflows. nyra health has done exactly that. Being reimbursed by 28+ insurers and recognized within Germany’s DRV standard of care means this is not a startup selling a nice-to-have wellness tool. It is a platform that clinics and payers have already validated with real money and real patients.

I find the €20 million raise to be bullish for several reasons. First, the combination of clinical evidence (26.2% health outcome improvement, 98% patient satisfaction) and regulatory certification (MDR Class IIa) puts nyra health in a different league than most digital therapy apps that rely on consumer downloads without clinical validation. Second, the U.S. market entry plan, backed by a pharmaceutical partnership and a €4.2 million university research collaboration, suggests a methodical approach rather than a rushed land grab.